Engflag

Eslo-AT

Quick links to important sections

Eslo-AT

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eslo-AT

Quick Facts

Property Description
Active ingredients Atenolol, Levamlodipine (S-Amlodipine)
Form Tablet (Fixed-Dose Combination)
Pharmacological class Antihypertensive Agent, Beta-Blocker, CCB
Common use Blood pressure control and angina management
Origin Synthetic chemical compounds

What Type of Medicine is Eslo-AT?

Eslo-AT is a synthetic, prescription-only Antihypertensive Agent formulated as a fixed-dose combination product for oral administration. The medication is engineered to merge two distinct drug classes: a Beta-Blocker and a Dihydropyridine Calcium Channel Blocker (CCB), creating a comprehensive single-tablet therapy. Fixed-dose combinations are a recognized strategy for improving control in patients with established hypertension. This indicates that the combination approach is a standard method for consistent patient management, particularly in adults who require dual pharmacological action.

Composition of Eslo-AT: A Dual-Action Formulation

The tablet contains two key active ingredients, Atenolol and Levamlodipine, which work together to achieve coordinated control over blood pressure. Atenolol functions as a cardioselective beta-blocker, contributing one half of the dual mechanism. The other half is supplied by Levamlodipine, which is the pharmacologically active isomer of the racemic compound Amlodipine. This specific form, also known as S-Amlodipine, is chosen to isolate the therapeutically active component. This dual-ingredient approach is utilized for addressing both heart rate and vascular tone simultaneously, which is beneficial for managing complex cardiovascular profiles.

General Purpose and Mechanism Principle

The general purpose of Eslo-AT is to provide effective, dual-action support for lowering elevated blood pressure and managing chest pain related to heart conditions. The combination facilitates two separate mechanisms: Atenolol reduces the force and frequency of the heart’s contractions, easing its overall workload. Concurrently, Levamlodipine promotes vasodilation by relaxing the blood vessels. This combined approach of a beta-blocker and a CCB is designed to address both cardiac output and peripheral resistance, and is frequently utilized when a patient’s blood pressure requires comprehensive management across both systems.

What side effects are possible with Eslo-AT?

Possible Side Effects and Safety Information

The regulatory safety profile for this fixed-dose combination, Eslo-AT (Atenolol and Levamlodipine), is based on the known safety characteristics and classifications of its two active components, as documented in official government sources.

Frequency-Classified and Systemic Effects

Adverse reactions are formally categorized by frequency. The very common effect associated with the Levamlodipine component is oedema (swelling), particularly ankle swelling, which is documented as dose-related. Common effects spanning both components include cardiovascular and nervous system events such as bradycardia (slow heart rate), cold extremities, fatigue, dizziness, somnolence, headache, and nausea.

Specific effects, including headache and dizziness, are reported to occur especially at the beginning of the treatment. The system-organ classes most frequently involved are Cardiac Disorders, Vascular Disorders, Nervous System Disorders, and General Disorders.

Serious Adverse Reactions and Regulatory Constraints

The regulatory label documents the potential for rare but serious adverse reactions. The Atenolol (beta-blocker) component is associated with a risk of worsening existing heart failure or the onset of overt cardiac failure. For the Levamlodipine component, the label notes the potential for worsening angina and acute myocardial infarction after starting or increasing the dose, particularly in high-risk patients. Severe dermatological reactions, such as Stevens-Johnson syndrome, have also been reported.

Key safety constraints documented in regulatory sources include a warning that the abrupt cessation or withdrawal of the Atenolol component should be avoided, as this may exacerbate symptoms of ischemic heart disease. Furthermore, specific caution is advised for older adults and patients with documented renal or severe hepatic impairment due to the component drugs’ elimination pathways.

Overdose and Emergency Response

Overexposure to the fixed-dose combination Eslo-AT is officially documented to result in serious, life-threatening cardiovascular manifestations, primarily stemming from the combined effects of the beta-blocker and calcium channel blocker components. Documented presentations include profound bradycardia (severely slow heart rate) and marked hypotension (critically low blood pressure) due to excessive peripheral vasodilation and depression of myocardial function. Severe outcomes listed in regulatory documents include cardiogenic shock and the risk of asystole or cardiac arrest.

Immediate medical attention is required for any suspected overdose. Due to the high risk of life-threatening events, the official guidance mandates that individuals contact emergency services immediately.

Regulatory information states that management is symptomatic and supportive. While no specific antidote is known for the calcium channel blocker component, interventions may include measures to reduce systemic absorption (such as gastric lavage or activated charcoal) and the use of pharmacological agents like Atropine or Glucagon to address specific cardiovascular findings. Extended hospital observation and continuous cardiac monitoring are explicitly required due to the long half-lives of the active ingredients. Overdose consequences may be more severe for patients with existing renal impairment.

Therapeutic Uses of Eslo-AT

What Eslo-AT treats: main uses and benefits

Eslo-AT is a combination medication primarily utilized for the management of cardiovascular conditions involving high blood pressure. It combines two different pharmacological agents, S-amlodipine and atenolol, which work through distinct mechanisms to help regulate blood pressure and reduce the workload on the heart.

Main Uses

  • Hypertension (High Blood Pressure): The primary use of this medication is to treat hypertension. It is often prescribed when a single medication is not sufficient to achieve target blood pressure levels. By lowering blood pressure, the medication helps manage a condition that, if left untreated, can lead to serious cardiovascular complications.
  • Chronic Stable Angina: In some cases, the components of this medication are used to manage chronic stable angina, a condition characterized by chest pain or discomfort occurring when the heart muscle does not receive enough oxygen-rich blood.

Mechanism of Action

This medication works by addressing blood pressure from two different angles:

  • Calcium Channel Blockade: The S-amlodipine component belongs to a class of drugs known as calcium channel blockers. It acts by relaxing the smooth muscles in the walls of the blood vessels, allowing them to widen. This reduces peripheral vascular resistance, making it easier for blood to flow through the body.
  • Beta-Adrenergic Blockade: The atenolol component is a beta-blocker. It works by blocking the effects of adrenaline on the heart. This action slows the heart rate and reduces the force of contraction, which lowers the heart's demand for oxygen and decreases the pressure within the circulatory system.

Benefits of the Combination

  • Improved Blood Pressure Control: By combining two different classes of antihypertensives, the medication can provide more effective blood pressure reduction than either component used alone at similar doses.
  • Cardiovascular Protection: Maintaining blood pressure within a healthy range is a critical factor in reducing the long-term risk of stroke, myocardial infarction (heart attack), and kidney problems.
  • Simplified Regimen: Combining two medications into a single tablet may assist patients in managing their treatment plan more easily, which can support consistent adherence to the prescribed therapy.

Regulatory References

  1. NIH NCBI StatPearls overview on Amlodipine

Eligibility and Restrictions for Use

Who Can and Cannot Use Eslo-AT: Official Regulatory Information

Eligibility for Eslo-AT is strictly defined by regulatory documents based on patient conditions and specific populations. The medicine is indicated for adults with essential hypertension.

Absolute Contraindications

The following conditions and patient groups must not use Eslo-AT:

  • Known hypersensitivity or allergy to Amlodipine, Atenolol, related drug classes, or any components.
  • Severe, uncontrolled cardiac conditions, including cardiogenic shock, overt cardiac failure, sinus bradycardia, and heart block greater than first-degree.
  • Severe hypotension (very low blood pressure) and bronchial asthma or other bronchospastic diseases.

Restrictions and Special Populations

Use is not established or not recommended for the following:

  • Pediatric Patients: Safety and efficacy are not established in individuals under 18 years of age.
  • Pregnancy: Use is generally contraindicated due to the risk of fetal harm.
  • Breastfeeding: Not recommended; potential for passage into breast milk and harm to the infant.
  • Organ Impairment: Patients with hepatic or renal impairment require caution, a lower starting dose, and careful monitoring, with use not recommended for severe impairment.
  • Other Conditions: Caution is required for patients with diabetes mellitus (due to masked hypoglycemia symptoms) and those with coronary artery disease.

What should I know about interactions with other medicines?

Eslo-AT Interactions with Other Medicines and Products

This section summarizes officially documented drug interactions for Eslo-AT (Levamlodipine/S-Amlodipine and Atenolol), based on government regulatory prescribing information. Interaction constraints are formally specified, with no therapeutic advice or mechanisms included.

Key Documented Interaction Categories

Category Interacting Substance/Product Regulatory Constraint and Effect
Contraindicated Combinations Verapamil, Diltiazem (Atenolol component) High-risk combination due to additive negative effects on heart conduction.
Metabolic Interactions CYP3A4 Inhibitors (e.g., Ketoconazole) Increases Levamlodipine systemic exposure.
CYP3A4 Inducers (e.g., Rifampin) May reduce Levamlodipine plasma concentration.
Pharmacodynamic Effects Other Antihypertensives Additive effects may increase the risk of hypotension.
Digoxin Risk of additive slowing of heart rate.

Specific Restrictions and Constraints

  • Simvastatin Restriction: Co-administration with the Levamlodipine component requires a specific limit on the maximum daily dose of Simvastatin to control increased exposure.
  • Timing Requirement: Administration of the Atenolol component must be separated by at least two hours from Multivitamin with Minerals to avoid reduced effectiveness.
  • Food/Product Cautions: Grapefruit juice may potentially increase Levamlodipine bioavailability. Alcohol is considered unsafe due to additive hypotensive effects.
  • Population Note: Caution regarding interactions with CYP3A4 inhibitors is explicitly advised in cases of Severe Hepatic Impairment.

Mechanism of Action

Eslo-AT is a fixed-dose combination containing S-Amlodipine and Atenolol, which acts through two distinct pathways to regulate cardiovascular function.

Regulation of Peripheral Vascular Tone

This domain involves the action of S-Amlodipine, which modulates key pathways associated with vascular smooth muscle contraction. It selectively inhibits the transmembrane influx of calcium ions into vascular smooth muscle cells via L-type calcium channels. This blockade reduces the intracellular calcium concentration, which is essential for muscle contraction. The resulting physiological consequence is the relaxation and widening of the arteries, also known as peripheral vasodilation. This action contributes to a decrease in resistance to blood flow throughout the body.

Modulation of Sympathetic Cardiac Signaling

This domain encompasses the action of Atenolol, a beta1-selective receptor antagonist. It specifically engages mechanisms that regulate overactive sympathetic nervous system processes on the heart. By blocking the binding of adrenaline and noradrenaline to the beta1 adrenergic receptors primarily in the heart, it suppresses the signaling sequences that normally increase cardiac activity. This modifies early molecular steps, leading to a reduction in the rate and force of heart muscle contraction. The resulting physiological effect is a decreased heart rate and reduced cardiac output, which is a state of reduced cardiac energy expenditure.

Dosage and Administration Information

How to use Eslo-AT

Eslo-AT is an oral, fixed-dose combination medication intended for long-term use, administered strictly as a tablet taken by mouth. The official administration schedule requires the medication to be taken once daily, with or without food, ideally at a consistent time each day to maintain stable systemic drug levels.

The standard adult regimen typically starts with one fixed-dose tablet, often combining 2.5 mg of Levamlodipine and 50 mg of Atenolol. Individual components have established maximum daily limits: the Levamlodipine dose should not exceed 5 mg, and the Atenolol dose is generally limited to 100 mg daily for hypertension.

If a dosage adjustment is required, the official protocol mandates a slow titration. Due to the prolonged time needed to assess the full effect of the Levamlodipine component, a period of seven to fourteen days must elapse between any dose changes. The tablet must be swallowed whole and should not be crushed or chewed, preserving the intended release profile.

Special consideration is required for specific populations. Official guidance recommends a lower initial dose for older adults and individuals with hepatic impairment. Furthermore, the dose must be adjusted in cases of renal impairment; for example, the maximum daily Atenolol component is reduced to 50 mg when Creatinine Clearance is between 15 mL/min and 35 mL/min. Lastly, the medication must never be stopped abruptly; instead, the dose must be gradually reduced over one to two weeks to avoid procedural complications inherent to the beta-blocker component.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eslo-AT

Evidence for use in Pain Management in Chronic Conditions

Research was studied for use in outcomes related to physical discomfort and conditions marked by functional limitations, such as chronic pain syndromes. The evidence includes short-term Randomized Controlled Trials (RCTs) and observational settings. These studies focused on measuring patient-reported outcomes describing perceived discomfort and functional activity levels in adult and elderly populations.

Studies report how symptoms evolved in the observed populations over time intervals generally limited to six months. Findings describe patterns observed across different chronic pain types, but results were mixed and heterogeneous across the study designs used. The research contributes to the broader evidence landscape related to how patients reported their experience of physical discomfort. Long-term effects are not fully established, as follow-up durations were limited.

Evidence for use in Insomnia and Sleep Disturbances

Eslo-AT was studied for use in sleep disturbances, including chronic insomnia. The available evidence comes from Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies monitored both subjective and objective sleep parameters, assessing outcomes related to systemic or functional imbalance (e.g., total sleep time) in adults with chronic sleep issues.

Trials report how symptoms evolved in the observed populations during the study period, typically over one to four weeks. Findings indicate patterns related to objective sleep measures and how participants reported their overall sleep quality. Long-term effects are not fully established for this indication, as the majority of studies were short-term, and certainty remains low regarding the persistence of any observed changes after the study period ends.

What is Still Uncertain About Eslo-AT Research

The research overall contributes to the broader evidence landscape, but the full picture is not yet complete. Data are still emerging, and certainty remains low in several key areas. A major gap is the lack of comprehensive long-term evidence to fully establish the persistence of any changes observed in the studies. Furthermore, evidence quality varies across studies due to factors like differing outcome measures, and data for certain groups remain insufficient, especially for populations with multiple complex medical conditions. These research limitations mean the studies help show what has been observed so far, but they do not provide a complete picture of potential outcomes.

Frequently Asked Questions (FAQ)

Common questions about Eslo-AT (FAQ)

Q: What happens if I stop taking Eslo-AT suddenly?

Official regulatory warnings advise against abruptly stopping this treatment because sudden withdrawal may exacerbate symptoms like chest pain (angina pectoris) or even trigger a heart attack. Dose reduction, if necessary, should be gradual over a period of one to two weeks, as directed by a healthcare provider.

Q: How quickly should I expect to see my blood pressure improve after starting Eslo-AT?

Regulatory documents state that seven to fourteen days should elapse to assess the full effect of any dose change for the Levamlodipine component. Clinical data for the individual medicines generally indicate that the maximum blood pressure-lowering effect from a new dose is typically seen within one to two weeks.

Q: Is it normal to feel dizzy or tired when I first start taking Eslo-AT?

Yes, regulatory documents indicate that dizziness and fatigue are common side effects associated with this medication. These effects, along with headache, are reported to occur especially during the initial stages of treatment.

Q: Does Eslo-AT cause weight gain or weight loss?

Official adverse reaction lists for the component drugs do not commonly or consistently list weight change, either weight gain or weight loss, as a frequent side effect.

Q: Can Eslo-AT affect my sleep patterns?

Official product information for the components indicates that sleep disturbances, including somnolence (sleepiness), can occur. These are documented as common or less common adverse reactions.

Q: Does Eslo-AT interact with common pain relievers like ibuprofen?

Yes, official drug interaction information advises caution regarding certain common pain relievers. Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, may potentially lessen the effectiveness of the Atenolol component in lowering blood pressure.

Q: Can Eslo-AT be split in half, or must I take the whole tablet?

Official guidance is that the tablet should be swallowed whole and not crushed or chewed. This is necessary to preserve the intended release profile and effectiveness of the fixed-dose combination.

Q: Why is S-Amlodipine used in Eslo-AT instead of regular Amlodipine?

The medication contains Levamlodipine (S-Amlodipine), which is the specific form that contains the desired therapeutic action. This pharmacologically active isomer is isolated and used to provide the effective component of the drug.

Q: Can Eslo-AT affect sexual function in men or women?

The official side effect profile for the Atenolol component includes reports of decreased sexual drive (libido) and impotence.

Q: Can taking Eslo-AT make my feet or ankles swell?

Yes, swelling, specifically oedema (fluid retention) of the ankles, is documented as a very common side effect. This reaction is primarily linked to the Levamlodipine component.

Q: Is it normal for my hands and feet to feel colder while on Eslo-AT?

Yes, cold extremities (hands and feet) is listed as a common adverse reaction for the medication. This effect is related to the action of the Atenolol component.

Q: What are the benefits of taking Eslo-AT compared to taking its components separately?

Fixed-dose combination products are designed primarily for convenience. Taking both active ingredients in a single tablet can help improve patient adherence (consistency) with their prescribed treatment plan.

Q: Why do doctors often prescribe combination drugs like Eslo-AT for hypertension?

Combination products are typically prescribed when a patient’s blood pressure is not adequately controlled by a single medication. This approach allows healthcare providers to address hypertension using two different mechanisms simultaneously.

Q: Is Eslo-AT considered a long-term treatment for blood pressure?

Yes, Eslo-AT is indicated for the treatment of hypertension (high blood pressure) and angina. Both of these are chronic conditions that require consistent, long-term therapeutic management.

Q: Can Eslo-AT cause any issues with liver or kidney function?

The component drugs are processed and eliminated by the liver and kidneys. Official guidance emphasizes caution and monitoring for patients with existing issues with their liver or kidney function.

Q: How long does Eslo-AT stay in your system after taking a dose?

The two active ingredients are eliminated at different rates. The Atenolol component has a shorter half-life of around 6 to 7 hours, while the Levamlodipine component stays in the system much longer, with an elimination half-life of approximately 30 to 50 hours.

Q: Can I take multivitamins or supplements with Eslo-AT?

If a multivitamin contains minerals, official guidance states the administration must be separated by at least two hours from the Atenolol component. This timing is necessary to avoid reduced effectiveness of the medicine.

Q: Does Eslo-AT affect my blood sugar levels?

The Atenolol component may mask the common physical signs and symptoms of hypoglycemia (low blood sugar). This is a specific concern for patients who have diabetes mellitus.

Q: Why is it important to check my heart rate while taking Eslo-AT?

The medication is known to cause a dose-related decrease in heart rate (bradycardia). Monitoring your heart rate is important because severe bradycardia is a contraindication for the medicine.

Q: What is the typical timeframe for a doctor to review my blood pressure after starting Eslo-AT?

Since the full therapeutic effect of any dose takes 1 to 2 weeks to be established, clinical follow-up and any subsequent dose adjustments are typically performed after a period of several days to two weeks.

Q: Can Eslo-AT be used for patients who have previously had a heart attack?

Yes, one of the components, Atenolol, is indicated in stable patients for improving survival after a known or suspected myocardial infarction (heart attack).

Q: Are there any specific laboratory tests needed while taking Eslo-AT?

Official guidance on the Atenolol component highlights the need for close monitoring of kidney function. This is necessary because the dose may need adjustment based on specific lab values if kidney function declines.

Q: Does Eslo-AT help improve chest pain (angina)?

The medication is officially indicated for the long-term management of angina pectoris (chest pain) that is related to coronary artery disease.

Q: Can I take over-the-counter cold and flu medicine with Eslo-AT?

Official warnings advise caution with taking over-the-counter (OTC) medicines for colds, coughs, hay fever, or sinus problems. These often contain ingredients that may increase blood pressure and counteract the effects of the Atenolol component.

Q: What should I tell my dentist before a procedure if I am taking Eslo-AT?

The regulatory label advises that if a patient requires surgery, the surgeon or anesthesiologist should be informed that the patient is taking the medication. The prescribing healthcare provider may need to make temporary adjustments to the regimen.

Q: Does Eslo-AT cause changes in mood or anxiety levels?

Official adverse reaction lists for the component drugs include reports of mood changes, depression, and anxiety, which are related to the central nervous system effects of the medication.

Q: Can Eslo-AT affect my ability to drive or operate machinery?

Regulatory documents caution that the common side effects, such as dizziness, somnolence (sleepiness), and fatigue, may impair your ability to drive or safely operate machinery.

Q: Is Eslo-AT used in the treatment of specific heart rhythm problems?

The Atenolol component has been used in the treatment of certain heart rhythm problems (arrhythmias).

Q: What kind of research supports the use of Eslo-AT for heart conditions?

Clinical trials support the use of the component drugs for lowering elevated blood pressure and managing angina pectoris (chest pain). These studies establish the basis for using the medication in adults with hypertension and coronary artery disease.

Q: What should I do if I miss a dose of Eslo-AT?

Regulatory guidance on a missed dose states that it should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, you should skip the missed dose and resume your regular schedule. It is important not to take a double dose to compensate for the missed one.

How should Eslo-AT be stored and disposed of?

How to Store and Dispose of Eslo-AT?

The official storage guidelines for Eslo-AT (Atenolol and Levamlodipine) are designed to maintain the product's stability and efficacy. The tablets must be stored at controlled room temperature, generally below 30 C (86 F). To protect the medicine from degradation, it is mandatory to keep it in the original container or package, ensuring it is tightly closed and shielded from both light and moisture.

Required Storage and Disposal Summary

Requirement Official Regulatory Instruction
Temperature Do not store above 30 C (Max)
Protection Keep in original packaging, protected from light and moisture.
Safety Keep out of the sight and reach of children and pets.
Disposal Dispose of unused or expired medicine according to local regulatory requirements (do not use household waste or wastewater).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Eslo-AT found in:

A-Z Index: